Analysts Maintain Prothena Price Target as Valuation Adjustments Reflect Recent Clinical Results

Analysts have increased their price target for Prothena significantly, raising it from $15 to $36. They cite the company's strong partnered pipeline as well as substantial potential from upcoming catalysts and milestone payments.

Analysts have marginally raised their price target for Prothena from $13.00 to $13.00. They cited slight adjustments in discount rate and profit margin assumptions as drivers for the updated valuation.

Analysts have raised Prothena's fair value estimate by $1.00 to $13.00, citing improved profit margin forecasts and a slightly lower projected future price-to-earnings ratio. What's in the News Prothena announced results from the Phase 1 ASCENT clinical program for PRX012 in early symptomatic Alzheimer's disease.

Prothena’s consensus price target has been revised down to $12.00, reflecting weaker expectations primarily due to a notable decline in net profit margin and a reduced future P/E multiple. What's in the News Prothena reported Phase 1 ASCENT program results for PRX012 in early symptomatic Alzheimer's, showing stable pharmacokinetics, low immunogenicity, significant amyloid reduction, but higher ARIA-E rates compared to FDA-approved antibodies; company plans to seek partnerships for PRX012 and PRX012-TfR.

Despite a sharp upward revision in both revenue growth and net profit margin forecasts for Prothena, the consensus analyst price target has significantly decreased from $24.29 to $15.00. What's in the News Phase 1 ASCENT results for PRX012 in early symptomatic Alzheimer's showed promising amyloid plaque reduction and pharmacokinetics, but higher ARIA-E rates than approved therapies; Prothena will seek partnership to advance PRX012 and its preclinical Ab-TfR antibody.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 81.7x to 91.2x.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased revenue growth from 23.1% to 16.4%, increased profit margin from 10.5% to 19.3%, increased future PE multiple from 58.3x to 81.4x and increased shares outstanding growth rate from 0.0% to 0.0%.